IDEAYA Biosciences (IDYA) Equity Average (2018 - 2026)

IDEAYA Biosciences has disclosed Equity Average across 9 years of filings, most recently posting $980.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at $980.1 million, down 5.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $980.1 million (down 5.91% YoY), and the FY2025 annual result was $1.0 billion, up 23.92% from the prior year.
• Equity Average came in at $980.1 million for Q1 2026 at IDEAYA Biosciences, down from $1.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.1 billion in Q4 2024 to a low of $279.0 million in Q2 2022.
• The 5-year median for Equity Average is $778.2 million (2024), against an average of $709.7 million.
• Across the five-year window, Equity Average jumped 127.79% in 2024 and fell 5.91% in 2026, its largest moves.
• IDEAYA Biosciences' Equity Average stood at $359.1 million in 2022, then jumped by 57.21% to $564.6 million in 2023, then soared by 98.34% to $1.1 billion in 2024, then dropped by 5.56% to $1.1 billion in 2025, then dropped by 7.32% to $980.1 million in 2026.
• The last three Equity Average figures came in at $980.1 million (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.